Am J Gastroenterol. 2024 Jan 1;119(1):55-80.doi: 10.14309/ajg.0000000000002485. Epub 2023 Aug 24.

Shannon Chang ¹, Megan Murphy, Lisa Malter

Author information

¹Division of Gastroenterology, Department of Medicine, New York University Langone Health, New York, New York, USA.

Abstract

The treatment armamentarium for inflammatory bowel disease has expanded rapidly in the past several years with new biologic and small molecule-agents approved for moderate-to-severe ulcerative colitis and Crohn's disease. This has made treatment selection more challenging with limited but evolving guidance as to where to position each medication. In this review, we discuss the efficacy data for each agent approved in the United States by reviewing their phase 3 trial data and other comparative effectiveness studies. In addition, safety considerations and use in special populations are summarized with proposed algorithms for positioning therapies. The aim is to provide a synopsis of high-impact data and aid in outpatient treatment decision-making for patients with inflammatory bowel disease.